期刊
ONCOGENE
卷 29, 期 16, 页码 2381-2392出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.9
关键词
neuropilin; glioma; angiogenesis; peptide; tumour growth
资金
- INSERM
- ACI JC [5327]
- ARC
- ANR Emergence bio
- FRC/Rotary international
- Pharmaxon
- La Ligue Contre le Cancer
Angiogenesis in glioblastoma is largely dependent on vascular endothelial growth factor (VEGF) signalling. Consistently, the VEGF coreceptor NRP1 promotes angiogenesis and tumour growth in gliomas. Here, we provide data showing that an innovative peptidic tool targeting the transmembrane domain of NRP1 efficiently blocks rat and human glioma growth in vivo. We show both in vivo and in vitro that the antitumour effect results from the anti-proliferative, anti-migratory and anti-angiogenic properties of the compound. The proposed NRP1 antagonizing peptide is therefore a promising novel class of anti-angiogenic drugs that might prolong glioma patient survival. Our results finally show for the first time that the transmembrane domain of important signalling receptors can be antagonized in vivo thereby providing a new avenue towards the development of atypical antagonists with strong therapeutic potential. Oncogene (2010) 29, 2381-2392; doi:10.1038/onc.2010.9; published online 8 February 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据